0001104659-23-100803.txt : 20230914 0001104659-23-100803.hdr.sgml : 20230914 20230914163111 ACCESSION NUMBER: 0001104659-23-100803 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230914 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230914 DATE AS OF CHANGE: 20230914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axcella Health Inc. CENTRAL INDEX KEY: 0001633070 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38901 FILM NUMBER: 231255472 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: THIRD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-868-0949 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: THIRD FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Pronutria Biosciences, Inc. DATE OF NAME CHANGE: 20150206 8-K 1 tm2326158d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 14, 2023

AXCELLA HEALTH INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38901		26-3321056
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

P.O. Box 1270 Littleton, Massachusetts	01460
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (857) 320-2200

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 Par Value		AXLA		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD.

Attached to this report on Form 8-K as Exhibit 99.1 is a copy of the press release dated September 14, 2023 titled “Axcella Announces Reverse Stock Split” whereby Axcella Health Inc. (the “Company”) announced that its Board of Directors has approved a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock. The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company’s common stock is expected to commence trading on a split-adjusted basis when the markets open on September 19, 2023 under the existing trading symbol “AXLA.”

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Reverse Stock Split and related timing. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, Quarterly Report on Form 10-Q for the three months ended June 30, 2023, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this Current Report on Form 8-K. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report on Form 8-K.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release titled “Axcella Announces Reverse Stock Split”, dated September 14, 2023
104		Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Axcella Health Inc.

Date: September 14, 2023	By:	/s/ William R. Hinshaw, Jr.
	Name:	/s/ William R. Hinshaw, Jr.
	Title:	President, Chief Executive Officer and Director

EX-99.1 2 tm2326158d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Axcella Announces Reverse Stock Split Effective September 19, 2023

– AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 –

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 14, 2023-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company’s common stock is expected to commence trading on a split-adjusted basis when the markets open on September 19, 2023 under the existing trading symbol “AXLA.” The new CUSIP number for the Company’s common stock following the reverse stock split will be 05454B204.

The primary goal of the reverse stock split is to increase the per share market price of the Company’s common stock to meet the minimum per share bid price requirement for continued listing on The Nasdaq Global Market. The reverse stock split was approved by the Company’s stockholders at its annual meeting of stockholders held on September 11, 2023. On September 11, 2023, following the annual meeting, the Company’s Board of Directors approved the reverse stock split at the ratio of 1-for-25. As a result of the reverse stock split, every twenty-five shares of the Company’s common stock issued and outstanding will be automatically reclassified into one new share of the Company’s common stock. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company’s outstanding equity awards, as applicable. The common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the reverse stock split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted to give effect to the reverse stock split) on The Nasdaq Global Market on September 18, 2023, the last trading day immediately preceding the effective time of the reverse stock split.

Computershare Trust Company, N.A. (“Computershare”), the Company’s transfer agent, is acting as the exchange agent for the reverse stock split. Stockholders with book-entry shares or who hold their shares through a bank, broker or other nominee will not need to take any action. Additional information about the reverse stock split can be found in the Company’s definitive proxy statement (the “Proxy Statement”) filed with the Securities and Exchange Commission (the “SEC”) on August 18, 2023, which is available free of charge at the SEC’s website, www.sec.gov, and on the Company’s website at https://axcellatx.com/.

Internet Posting of Information

Axcella uses the “Investors and News” section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

About Axcella Therapeutics (Nasdaq: AXLA)

Axcella is a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs). The company’s unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements concerning the expected timing of the reverse stock split, the impact of the reverse stock split on the Company’s share price, and the Company’s ability to meet the minimum per share bid price requirement for continued listing on The Nasdaq Global Market.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential volatility of our common stock; and the potential delisting of our common stock from The Nasdaq Global Market. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, our Quarterly Report on Form 10-Q for the three months ended June 30, 2023, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Company Contact

ir@axcellatx.com

(857) 320-2200

EX-101.SCH 3 axla-20230914.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 axla-20230914_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 axla-20230914_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 14, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 14, 2023
Entity File Number	001-38901
Entity Registrant Name	AXCELLA HEALTH INC.
Entity Central Index Key	0001633070
Entity Tax Identification Number	26-3321056
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	P.O. Box 1270
Entity Address, City or Town	Littleton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01460
City Area Code	857
Local Phone Number	320-2200
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 Par Value
Trading Symbol	AXLA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 7 tm2326158d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001633070 2023-09-14 2023-09-14 iso4217:USD shares iso4217:USD shares 0001633070 false 8-K 2023-09-14 AXCELLA HEALTH INC. DE 001-38901 26-3321056 P.O. Box 1270 Littleton MA 01460 857 320-2200 false false false false Common Stock, $0.001 Par Value AXLA NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://axcellahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2326158d1_8k.htm axla-20230914.xsd axla-20230914_lab.xml axla-20230914_pre.xml tm2326158d1_ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2326158d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2326158d1_8k.htm" ] }, "labelLink": { "local": [ "axla-20230914_lab.xml" ] }, "presentationLink": { "local": [ "axla-20230914_pre.xml" ] }, "schema": { "local": [ "axla-20230914.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "axla", "nsuri": "http://axcellahealth.com/20230914", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2326158d1_8k.htm", "contextRef": "AsOf2023-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://axcellahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2326158d1_8k.htm", "contextRef": "AsOf2023-09-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://axcellahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-100803-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-100803-xbrl.zip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end